FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
HealthDay on MSN6 天
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
Endocrinology Advisor1 天
Gemtesa Approved for Men With OAB Symptoms Receiving BPH Treatment
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
McKnight's Senior Living7 天
FDA approves Gemtesa for overactive bladder in men with BPH
(HealthDay News) — Gemtesa (vibegron) has been approved by the US Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...
Too Old to Operate6 天
FDA Approves Gemtesa for Overactive Bladder in Men With BPH
THURSDAY, Jan. 2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...
Renal & Urology News10 天
Gemtesa Approved for Men With OAB Symptoms Receiving BPH Treatment
The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive bladder (OAB ... is an important milestone for the men with unresolved symptoms of ...
pharmaphorum3 天
FDA approves Adstiladrin as first gene therapy for NMIBC
According to the Centers for Disease Control and Prevention, about 57,000 men and ... adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.
Medindia12 小时
Could Targeted Steam Therapy Cure Prostate Cancer?
A new clinical trial explores whether targeted steam therapy can offer a less invasive, effective treatment for prostate ...